← Back

Novogene Co. Ltd.

Novogene Co., Ltd. provides genomic services and solutions through its subsidiaries in Mainland China, Hong Kong, Macau, Taiwan, and internationally. Its offerings include genomic sequencing, transcriptomics, epigenomics, single-cell and spatial transcriptomics, proteomics, clinical diagnostics, and biopharma services. The company also offers sequencing platforms under the ILLUMINA, PACBIO, 10X GENOMICS, and NANOPORE brands, along with basic scientific research and medical research services. Founded in 2011 and headquartered in Beijing, China, Novogene serves research universities, institutes, hospitals, pharmaceutical R&D companies, and agricultural companies.

Price · split & dividend adjusted
News & notes moving 688315.CG
688315.CG2

Novogene's 2026 interim report shows net profit of 63.12 million yuan, down 19.82% year-on-year

Novogene released its 2026 interim report, with total operating revenue of 1.114 billion yuan and net profit attributable to the parent company of 63.12 million yuan, a decrease of 19.82% compared with the same period last year. Net cash flow from operating activities was negative 32.38 million yuan, ranking 26th among disclosed peer companies. The company's asset-liability ratio was 30.39%, gross margin was 41.86%, return on equity was 2.35%, and diluted earnings per share was 0.16 yuan, down 15.79% from the same period last year. The number of shareholders was 9,114, and the top ten shareholders held 71.87% of the total share capital.
Jiemian·24dRead more →